Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The AMADEUS trial, a multicenter, randomized, open-label, assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SR34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation

Trial Profile

The AMADEUS trial, a multicenter, randomized, open-label, assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SR34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idraparinux sodium (Primary) ; Acenocoumarol; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational
  • Acronyms AMADEUS
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Jul 2020 Results (n=4554) of post-hoc analysis evaluating the impact of renal failure on major adverse cardiovascular events (MACE) in AF, and predictive value of the 2MACE score published in the American Journal of Cardiology
    • 02 May 2018 Results of post hoc analysis comparing data from Murcia AF Project and the AMADEUS trial published in the Mayo Clinic Proceedings
    • 01 Dec 2015 Post hoc analysis results (n=1588) from elderly patients with respect Body Mass Index published in the Stroke.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top